Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration

AstraZeneca

Status and phase: Suspended; Phase 1

Conditions: Metabolism; Excretion; Absorption; Distribution

Treatments: Drug: AZD7325

Study type: Interventional

Funder types: Industry

Identifiers

NCT00940641

D1140C00017

Details and patient eligibility

About

The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of AZD7325 after intravenous and 14C labeled oral dose

Enrollment: 8 estimated patients

Sex: Male

Ages: 35 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy subjects Day 1
• Body Mass Index (BMI) > 18 and < 30kg/m2

Exclusion criteria

• Clinically relevant disease and abnormalities (past or present) which in the opinion of the investigator, may either put the subject at risk to participate in this study or may influence the results of the study or the subject's ability to participate in the study
• Use of prescription medication within 14 days of the first dose of the investigational product
• Blood loss in excess of 200 mL within 30 days of Day-1 in excess of 500 mL within 90 days of Day-1 or in excess of 1350 mL within 1 year of Day-1 or donation of blood products within 14 days of Day -1

Trial design

8 participants in 2 patient groups

1

Experimental group

Description:

IV dose of AZD7325

Treatment:

Drug: AZD7325

Drug: AZD7325

2

Experimental group

Description:

14C oral dose of AZD7325

Treatment:

Drug: AZD7325

Drug: AZD7325